Most of the clinical trial participants are not able to receive any information about whether or not the clinical trial drug has been/will be released to the public, even though this may be information that they are extremely interested in. To solve this issue, 3H uses its own IT technology to support the distribution of that data to clinical trial participants. We believe that this initiative will help to improve social recognition of clinical trials. As more patients begin to participate in clinical trials, drug development as a whole will become more efficient. Furthermore, the people who actually participate in clinical trials are just a fraction of those that have applied to do so. So if you include those that didn’t pass the screening stage at the contact center, the number of people cooperating with any given clinical trial multiplies by 10 to 20 fold. The qualitative and quantitative information that is collected through exchanges with the contact center becomes the “patient’s voice” and can be also be used for strategic marketing purposes once the product has entered the market. This is why 3H believes that supporting the distribution of information about medicines is of utmost importance.
